Over
the last decades, the scientific interest in chemistry and pharmacology of
cannabinoids has increased. Most attention has focused on ∆9-tetrahydrocannabinol
(∆9-THC) as it is the psychoactive constituent of Cannabis sativa
(C. sativa). However, in previous years, the focus of interest in the second
plant constituent with non-psychotropic properties, cannabidiol (CBD) has been
enhanced. Recently, several groups have investigated the pharmacological
properties of CBD with significant findings; furthermore, this compound has
raised promising pharmacological properties as a wake-inducing drug. In the
current review, we will provide experimental evidence regarding the potential
role of CBD as a wake-inducing drug.
Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20 μg/1 μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.